Insulin glargine 300 U/mLand insulin degludec: A review of the current evidence comparing these two second-generation basal insulin analogues
Por:
Cheng, AL, Bailey, TS, Mauricio, D, Roussel, R
Publicada:
1 oct 2020
Ahead of Print:
1 jun 2020
Resumen:
For most people with type 2 diabetes (T2D), treatment intensification with the addition of basal insulin therapy is required to maintain glycaemic control. However, this often does not happen in real-life practice promoting the development of long-term diabetes-related complications. The second-generation basal insulin analogues glargine 300 U/mL (Gla-300) and degludec (IDeg) provide pharmacokinetic and pharmacodynamic improvements that may allow them to be more effective in appropriately managing diabetes compared with first-generation basal insulin analogues. Both Gla-300 and IDeg have been extensively studied vs the first-generation basal insulin glargine 100 U/mL, demonstrating comparable efficacy in terms of glycaemic control, and a lower risk of hypoglycaemia. The BRIGHT randomized controlled trial is the first direct comparison of the efficacy and safety profiles of Gla-300 and IDeg in patients with T2D. Moreover, real-world data have been used to assess the effectiveness of these basal insulins during routine clinical practice. Further research is required to determine if the properties of Gla-300 and IDeg may lead to improvements in healthcare-related costs and the quality of life of patients, which are important factors for informing clinical decisions.
Filiaciones:
Cheng, AL:
Univ Toronto, Div Endocrinol & Metab, Toronto, ON, Canada
Bailey, TS:
AMCR Inst, Escondido, CA USA
Mauricio, D:
Hosp Santa Creu Sant i Pau, Dept Endocrinol & Nutr, CIBER Diabet & Associated Metab Dis, Barcelona, Spain
Roussel, R:
Hop Bichat Claude Bernard, AP HP, Diabetol Endocrinol Nutr, Paris, France
INSERM, Ctr Rech Cordeliers, U 1138, Paris, France
Paris Univ, UFR Med, Paris, France
|